Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial

Inclusion Criteria: 1. Patient is indicated for left ventricular support according to current medical guidelines ("current medical guidelines" applies only to patients enrolled in Germany) 2. Patient has a cardiac index of \< 2.2 L/min/m2 and is being treated with at least one moderate dose inotrope or at least one moderate dose of vasopressor (e.g., milrinone ≥0.3 mcg/kg/min, dopamine \> 5 mcg/kg/min, dobutamine \> 5 mcg/kg/min) AND: * PCWP \> 18 mmHg, AND * Systolic blood pressure \< 100 mmHg, AND * Decreased organ perfusion as evidenced by urine output of 50 mL/hr OR increased creatinine of 0.3 mg/dl from baseline obtained within 2 weeks, OR cool extremities 3. Written, signed, and dated informed consent Exclusion Criteria: 1. Patient is \>85 years of age 2. Right ventricular failure requiring mechanical circulatory support 3. ST elevation myocardial infarction (STEMI) within 30 days of procedure 4. Cardiac arrest within 7 days of procedure requiring CPR 5. Current treatment with mechanical circulatory device such as IABP, ECMO, centrifugal pump, etc. 6. Documented acute myocarditis 7. Active major cardiac rhythm disturbances (e.g., ventricular tachycardia, ventricular fibrillation). 8. Hypertrophic disease or any left ventricular outflow tract obstruction 9. Active sepsis defined as bacteremia, fever ≥ 101.5 degrees F 10. Mural thrombus in the left ventricle 11. History of aortic valve replacement 12. End-stage renal disease requiring dialysis 13. Documented presence of aortic stenosis (orifice area of 1.5 cm2 or less) 14. Moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as 2 or higher) 15. Platelet count \< 100,000 16. Allergy or Intolerance to heparin, aspirin, clopidogrel, ionic and nonionic contrast media, or any other potentially required anticoagulants or antiplatelet therapy drugs 17. Known coagulopathies 18. Presence of risk factors for severe liver and/or renal dysfunction 19. Stroke within 90 days of enrollment 20. Significant peripheral vascular disease 21. History of heparin induced thrombocytopenia 22. Patient is pregnant or planning to become pregnant during the study period 23. Patient is breastfeeding. 24. Any active disease (e.g., active cancer) which could affect the patient's participation in the study, or if life expectancy is less than 1 year. 25. Any active disease in which the investigator determines would make the patient an inappropriate candidate for the study. 26. Participation in another clinical study of an investigational drug or device that has not met its primary endpoint